arrow
M

Matthew Thorpe

department of radiology
H指数:18
被引数:1,630

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PSMA-RECAP: [177Lu]Lu-PSMA-617 retreatment in metastatic castration-resistant prostate cancer

PSMA-RECAP:[177Lu]Lu-PSMA-617重复治疗转移性去势抵抗性前列腺癌

2026-08-310
OA
Outcomes of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Patients with Metastatic Pheochromocytoma and Paraganglioma

177Lu-DOTATATE肽受体放射性核素治疗在转移性嗜铬细胞瘤和副神经节瘤患者中的疗效

2026-01-010
PRE
Refining PET-based response in extramedullary multiple myeloma using total lesion glycolysis

基于总病灶糖酵解对外周多发性骨髓瘤的PET反应进行优化

Leukemia
IF13.4
2025-09-280
PRE
Outcomes for [177Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate Cancer

[177Lu]Lu-PSMA-617在有和无雄激素受体通路抑制剂联合使用情况下,在转移性去势抵抗性前列腺癌患者中的疗效

2025-08-050
PRE
[177Lu] Lu-PSMA-617 treatment for metastatic castration-resistant prostate cancer (mCRPC) with cerebral and cerebellar metastases

[177Lu] Lu-PSMA-617治疗伴有脑部和脑桥部转移的转移性去势抵抗性前列腺癌(mCRPC)

2025-07-210
PRE
Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [177Lu]Lu- PSMA-617

接受 [177Lu]Lu- PSMA-617治疗的转移性去势抵抗性前列腺癌和肝转移患者的预后

2024-10-300
PRE
Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity
2023-08-188
OAAI
Factors Influential in the Selection of Radiology Residents in the Post-Step 1 World: A Discrete Choice Experiment
2021-11-0114
PREAI